Mackenzie Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Mackenzie Financial’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.1M	Buy	91,604 +60,096	+191%	+$2M	﹤0.01%	948
2026 Q1	$949K	Buy	31,508 +4,766	+18%	+$153K	﹤0.01%	1086
2025 Q4	$836K	Sell	26,742 -2,115	-7%	-$52.1K	﹤0.01%	1108
2025 Q3	$583K	Sell	28,857 -203	-0.7%	-$3.56K	﹤0.01%	1208
2025 Q2	$487K	Hold	29,060	–	–	﹤0.01%	1236
2025 Q1	$447K	Sell	29,060 -829	-3%	-$14.8K	﹤0.01%	1233
2024 Q4	$659K	Buy	29,889 +1,171	+4%	+$21.3K	﹤0.01%	1060
2024 Q3	$517K	Sell	28,718 -13,600	-32%	-$238K	﹤0.01%	1011
2024 Q2	$688K	Sell	42,318 -52,800	-56%	-$813K	﹤0.01%	936
2024 Q1	$1.34M	Buy	95,118 +65,164	+218%	+$821K	﹤0.01%	819
2023 Q4	$313K	Hold	29,954	–	–	﹤0.01%	1138
2023 Q3	$288K	Hold	29,954	–	–	﹤0.01%	1155
2023 Q2	$224K	Hold	29,954	–	–	﹤0.01%	1296
2023 Q1	$265K	Sell	29,954 -1,153	-4%	-$11.4K	﹤0.01%	1235
2022 Q4	$284K	Sell	31,107 -3,562	-10%	-$31.1K	﹤0.01%	1106
2022 Q3	$280K	Hold	34,669	–	–	﹤0.01%	1115
2022 Q2	$261K	Buy	34,669 +2,349	+7%	+$20.5K	﹤0.01%	1156
2022 Q1	$303K	Sell	32,320 -21,746	-40%	-$181K	﹤0.01%	1107
2021 Q4	$433K	Buy	54,066 +1,747	+3%	+$15.8K	﹤0.01%	1025
2021 Q3	$510K	Buy	52,319 +31,391	+150%	+$294K	﹤0.01%	997
2021 Q2	$207K	Hold	20,928	–	–	﹤0.01%	1164
2021 Q1	$242K	Hold	20,928	–	–	﹤0.01%	1054
2020 Q4	$202K	Hold	20,928	–	–	﹤0.01%	996
2020 Q3	$189K	Sell	20,928 -90,000	-81%	-$952K	﹤0.01%	934
2020 Q2	$1.37M	Sell	110,928 -12,441	-10%	-$141K	﹤0.01%	625
2020 Q1	$1.11M	Buy	123,369 +102,441	+489%	+$1.05M	﹤0.01%	621
2019 Q4	$205K	Hold	20,928	–	–	﹤0.01%	1037
2019 Q3	$144K	Hold	20,928	–	–	﹤0.01%	976
2019 Q2	$193K	Hold	20,928	–	–	﹤0.01%	1038
2019 Q1	$328K	Sell	20,928 -180,130	-90%	-$3.18M	﹤0.01%	1095
2018 Q4	$3.1M	Buy	201,058 +52,858	+36%	+$1.08M	0.01%	618
2018 Q3	$3.19M	Buy	148,200 +103,000	+228%	+$2.39M	0.01%	570
2018 Q2	$1.1M	Hold	45,200	–	–	﹤0.01%	673
2018 Q1	$772K	Sell	45,200 -196,800	-81%	-$3.84M	﹤0.01%	667
2017 Q4	$4.59M	Sell	242,000 -1,494,434	-86%	-$22.5M	0.01%	441
2017 Q3	$30.6M	Buy	1,736,434 +1,402,230	+420%	+$31.6M	0.16%	152
2017 Q2	$11.1M	Buy	334,204 +27,342	+9%	+$846K	0.06%	238
2017 Q1	$9.85M	Buy	306,862 +11,419	+4%	+$390K	0.06%	241
2016 Q4	$10.7M	Buy	295,443 +90,360	+44%	+$3.61M	0.06%	224
2016 Q3	$9.44M	Sell	205,083 -335,015	-62%	-$17.5M	0.06%	215
2016 Q2	$27.1M	Buy	540,098 +127,543	+31%	+$6.79M	0.15%	157
2016 Q1	$22.1M	Sell	412,555 -6,348	-2%	-$372K	0.2%	127
2015 Q4	$27.5M	Buy	418,903 +29,849	+8%	+$1.84M	0.17%	135
2015 Q3	$22M	Sell	389,054 -61,073	-14%	-$3.96M	0.13%	160
2015 Q2	$26.6M	Buy	450,127 +112,437	+33%	+$6.94M	0.14%	158
2015 Q1	$21M	Buy	337,690 +103,890	+44%	+$6.04M	0.11%	180
2014 Q4	$13.4M	Buy	233,800 +21,330	+10%	+$1.19M	0.07%	218
2014 Q3	$11.4M	Buy	212,470 +195,470	+1,150%	+$10.4M	0.06%	244
2014 Q2	$891K	Hold	17,000	–	–	﹤0.01%	529
2014 Q1	$898K	Sell	17,000 -8,000	-32%	-$370K	﹤0.01%	523
2013 Q4	$1M	Sell	25,000 -990	-4%	-$39K	0.01%	488
2013 Q3	$982K	Buy	25,990 +80	+0.3%	+$3.12K	0.01%	484
2013 Q2	$1.02M	Buy	+25,910	New	+$1.01M	﹤0.01%	490

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Mackenzie Financial's TEVA Position: Q2 2026 in Review

Mackenzie Financial increased its Teva Pharmaceuticals (TEVA) stake by 191% in Q2 2026, buying an estimated $2M and bringing the position to 91,604 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #948.

Mackenzie Financial first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $30.6M in Q3 2017. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Mackenzie Financial held 91,604 shares of Teva Pharmaceuticals worth $3.1M as of Q2 2026.
Mackenzie Financial bought 60,096 Teva Pharmaceuticals shares in Q2 2026, an estimated $2M.
Teva Pharmaceuticals made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #948 holding.
Mackenzie Financial first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Mackenzie Financial's Teva Pharmaceuticals position peaked at $30.6M in Q3 2017.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.